Reference  ||| S:0 E:10 ||| NN
values  ||| S:10 E:17 ||| NNS
of  ||| S:17 E:20 ||| IN
lymphocyte  ||| S:20 E:31 ||| JJ
sub-populations  ||| S:31 E:47 ||| NN
in  ||| S:47 E:50 ||| IN
healthy  ||| S:50 E:58 ||| JJ
human  ||| S:58 E:64 ||| JJ
immunodeficiency  ||| S:64 E:81 ||| FW
virus-negative  ||| S:81 E:96 ||| FW
Iranian  ||| S:96 E:104 ||| FW
adults  ||| S:104 E:111 ||| FW
Lymphocyte  ||| S:111 E:122 ||| FW
subsets  ||| S:122 E:130 ||| FW
enumeration  ||| S:130 E:142 ||| FW
is  ||| S:142 E:145 ||| VBZ
considered  ||| S:145 E:156 ||| VBN
prominent  ||| S:156 E:166 ||| JJ
in  ||| S:166 E:169 ||| IN
the  ||| S:169 E:173 ||| DT
management  ||| S:173 E:184 ||| NN
of  ||| S:184 E:187 ||| IN
primary  ||| S:187 E:195 ||| JJ
and  ||| S:195 E:199 ||| CC
acquired  ||| S:199 E:208 ||| VBD
immunodeficiency  ||| S:208 E:225 ||| JJ
disorders ||| S:225 E:234 ||| NNS
.  ||| S:234 E:236 ||| .
Because  ||| S:236 E:244 ||| IN
of  ||| S:244 E:247 ||| IN
local  ||| S:247 E:253 ||| JJ
variations  ||| S:253 E:264 ||| NNS
due  ||| S:264 E:268 ||| JJ
to  ||| S:268 E:271 ||| TO
race ||| S:271 E:275 ||| NN
,  ||| S:275 E:277 ||| ,
age ||| S:277 E:280 ||| NN
,  ||| S:280 E:282 ||| ,
gender ||| S:282 E:288 ||| NN
,  ||| S:288 E:290 ||| ,
and  ||| S:290 E:294 ||| CC
environmental  ||| S:294 E:308 ||| JJ
conditions  ||| S:308 E:319 ||| NNS
on  ||| S:319 E:322 ||| IN
lymphocyte  ||| S:322 E:333 ||| JJ
subsets ||| S:333 E:340 ||| NN
,  ||| S:340 E:342 ||| ,
and  ||| S:342 E:346 ||| CC
to  ||| S:346 E:349 ||| TO
improve  ||| S:349 E:357 ||| VB
the  ||| S:357 E:361 ||| DT
accuracy  ||| S:361 E:370 ||| NN
of  ||| S:370 E:373 ||| IN
interpretation  ||| S:373 E:388 ||| NN
of  ||| S:388 E:391 ||| IN
laboratory  ||| S:391 E:402 ||| NN
findings ||| S:402 E:410 ||| NNS
,  ||| S:410 E:412 ||| ,
reference  ||| S:412 E:422 ||| NN
intervals  ||| S:422 E:432 ||| NNS
must  ||| S:432 E:437 ||| MD
be  ||| S:437 E:440 ||| VB
determined  ||| S:440 E:451 ||| VBN
in  ||| S:451 E:454 ||| IN
every  ||| S:454 E:460 ||| DT
population ||| S:460 E:470 ||| NN
.  ||| S:470 E:472 ||| .
To  ||| S:472 E:475 ||| TO
establish  ||| S:475 E:485 ||| VB
a  ||| S:485 E:487 ||| DT
normal  ||| S:487 E:494 ||| JJ
reference  ||| S:494 E:504 ||| NN
range  ||| S:504 E:510 ||| NN
for  ||| S:510 E:514 ||| IN
CD3+ ||| S:514 E:518 ||| NNP
,  ||| S:518 E:520 ||| ,
CD4+ ||| S:520 E:524 ||| NNP
,  ||| S:524 E:526 ||| ,
CD8+ ||| S:526 E:530 ||| NNP
,  ||| S:530 E:532 ||| ,
CD19+  ||| S:532 E:538 ||| NNP
and  ||| S:538 E:542 ||| CC
CD56+  ||| S:542 E:548 ||| CD
lymphocytes  ||| S:548 E:560 ||| NN
in  ||| S:560 E:563 ||| IN
a  ||| S:563 E:565 ||| DT
healthy  ||| S:565 E:573 ||| JJ
Iranian  ||| S:573 E:581 ||| JJ
adult  ||| S:581 E:587 ||| NN
population  ||| S:587 E:598 ||| NN
using  ||| S:598 E:604 ||| VBG
flowcytometry ||| S:604 E:617 ||| NNS
.  ||| S:617 E:619 ||| .
Blood  ||| S:619 E:625 ||| NN
samples  ||| S:625 E:633 ||| NNS
were  ||| S:633 E:638 ||| VBD
collected  ||| S:638 E:648 ||| VBN
from  ||| S:648 E:653 ||| IN
221  ||| S:653 E:657 ||| CD
HIV  ||| S:657 E:661 ||| JJ
seronegative  ||| S:661 E:674 ||| JJ
individuals ||| S:674 E:685 ||| NNS
,  ||| S:685 E:687 ||| ,
including  ||| S:687 E:697 ||| VBG
112  ||| S:697 E:701 ||| CD
females  ||| S:701 E:709 ||| NNS
and  ||| S:709 E:713 ||| CC
109  ||| S:713 E:717 ||| CD
males ||| S:717 E:722 ||| NNS
,  ||| S:722 E:724 ||| ,
with  ||| S:724 E:729 ||| IN
ages  ||| S:729 E:734 ||| NNS
ranging  ||| S:734 E:742 ||| VBG
from  ||| S:742 E:747 ||| IN
20  ||| S:747 E:750 ||| CD
to  ||| S:750 E:753 ||| TO
40  ||| S:753 E:756 ||| CD
years  ||| S:756 E:762 ||| NNS
old ||| S:762 E:765 ||| JJ
.  ||| S:765 E:767 ||| .
The  ||| S:767 E:771 ||| DT
percentage  ||| S:771 E:782 ||| NN
of  ||| S:782 E:785 ||| IN
lymphocytes  ||| S:785 E:797 ||| JJ
expressing  ||| S:797 E:808 ||| NN
either  ||| S:808 E:815 ||| CC
of  ||| S:815 E:818 ||| IN
CD3 ||| S:818 E:821 ||| NNP
,  ||| S:821 E:823 ||| ,
CD4 ||| S:823 E:826 ||| NNP
,  ||| S:826 E:828 ||| ,
CD8 ||| S:828 E:831 ||| NNP
,  ||| S:831 E:833 ||| ,
CD19  ||| S:833 E:838 ||| NNP
and  ||| S:838 E:842 ||| CC
CD56  ||| S:842 E:847 ||| CD
surface  ||| S:847 E:855 ||| NN
markers  ||| S:855 E:863 ||| NNS
were  ||| S:863 E:868 ||| VBD
determined  ||| S:868 E:879 ||| VBN
by  ||| S:879 E:882 ||| IN
flowcytometry  ||| S:882 E:896 ||| JJ
assay ||| S:896 E:901 ||| NN
.  ||| S:901 E:903 ||| .
Total  ||| S:903 E:909 ||| JJ
mean  ||| S:909 E:914 ||| JJ
percentage  ||| S:914 E:925 ||| NN
and  ||| S:925 E:929 ||| CC
absolute  ||| S:929 E:938 ||| JJ
count  ||| S:938 E:944 ||| NN
of  ||| S:944 E:947 ||| IN
lymphocyte  ||| S:947 E:958 ||| JJ
subsets  ||| S:958 E:966 ||| NN
were  ||| S:966 E:971 ||| VBD
as  ||| S:971 E:974 ||| RB
follows ||| S:974 E:981 ||| VBZ
:  ||| S:981 E:983 ||| :
CD3+ ||| S:983 E:987 ||| CD
:  ||| S:987 E:989 ||| :
70.90  ||| S:989 E:995 ||| CD
±  ||| S:995 E:997 ||| CD
7.54 ||| S:997 E:1001 ||| CD
% ||| S:1001 E:1002 ||| NN
,  ||| S:1002 E:1004 ||| ,
1800.87  ||| S:1004 E:1012 ||| FW
±  ||| S:1012 E:1014 ||| FW
471.09  ||| S:1014 E:1021 ||| FW
cells ||| S:1021 E:1026 ||| FW
/ ||| S:1026 E:1027 ||| FW
µl ||| S:1027 E:1029 ||| FW
;  ||| S:1029 E:1031 ||| :
CD4+ ||| S:1031 E:1035 ||| CD
:  ||| S:1035 E:1037 ||| :
41.04  ||| S:1037 E:1043 ||| CD
±  ||| S:1043 E:1045 ||| CD
7.86 ||| S:1045 E:1049 ||| CD
% ||| S:1049 E:1050 ||| NN
,  ||| S:1050 E:1052 ||| ,
1039.99  ||| S:1052 E:1060 ||| FW
±  ||| S:1060 E:1062 ||| FW
338.02  ||| S:1062 E:1069 ||| FW
cells ||| S:1069 E:1074 ||| FW
/ ||| S:1074 E:1075 ||| FW
µl ||| S:1075 E:1077 ||| FW
;  ||| S:1077 E:1079 ||| :
CD8+ ||| S:1079 E:1083 ||| CD
:  ||| S:1083 E:1085 ||| :
31.11  ||| S:1085 E:1091 ||| CD
±  ||| S:1091 E:1093 ||| CD
6.60 ||| S:1093 E:1097 ||| CD
% ||| S:1097 E:1098 ||| NN
,  ||| S:1098 E:1100 ||| ,
783.95  ||| S:1100 E:1107 ||| FW
±  ||| S:1107 E:1109 ||| FW
234.87  ||| S:1109 E:1116 ||| FW
cells ||| S:1116 E:1121 ||| FW
/ ||| S:1121 E:1122 ||| FW
µl ||| S:1122 E:1124 ||| FW
;  ||| S:1124 E:1126 ||| :
CD19+ ||| S:1126 E:1131 ||| CD
:  ||| S:1131 E:1133 ||| :
12.77  ||| S:1133 E:1139 ||| CD
±  ||| S:1139 E:1141 ||| CD
4.56 ||| S:1141 E:1145 ||| CD
% ||| S:1145 E:1146 ||| NN
,  ||| S:1146 E:1148 ||| ,
328.37  ||| S:1148 E:1155 ||| FW
±  ||| S:1155 E:1157 ||| FW
153.17  ||| S:1157 E:1164 ||| FW
cells ||| S:1164 E:1169 ||| FW
/ ||| S:1169 E:1170 ||| FW
µl ||| S:1170 E:1172 ||| FW
;  ||| S:1172 E:1174 ||| :
CD56+ ||| S:1174 E:1179 ||| CD
:  ||| S:1179 E:1181 ||| :
15.53  ||| S:1181 E:1187 ||| CD
±  ||| S:1187 E:1189 ||| CD
6.34 ||| S:1189 E:1193 ||| CD
% ||| S:1193 E:1194 ||| NN
,  ||| S:1194 E:1196 ||| ,
388.62  ||| S:1196 E:1203 ||| FW
±  ||| S:1203 E:1205 ||| FW
176.17  ||| S:1205 E:1212 ||| FW
cells ||| S:1212 E:1217 ||| FW
/ ||| S:1217 E:1218 ||| FW
µl ||| S:1218 E:1220 ||| FW
,  ||| S:1220 E:1222 ||| ,
respectively ||| S:1222 E:1234 ||| RB
.  ||| S:1234 E:1236 ||| .
The  ||| S:1236 E:1240 ||| DT
ratio  ||| S:1240 E:1246 ||| NN
of  ||| S:1246 E:1249 ||| IN
CD4+ ||| S:1249 E:1253 ||| CD
/ ||| S:1253 E:1254 ||| CD
CD8+  ||| S:1254 E:1259 ||| CD
lymphocytes  ||| S:1259 E:1271 ||| NN
for  ||| S:1271 E:1275 ||| IN
the  ||| S:1275 E:1279 ||| DT
studied  ||| S:1279 E:1287 ||| JJ
population  ||| S:1287 E:1298 ||| NN
was  ||| S:1298 E:1302 ||| VBD
1.39  ||| S:1302 E:1307 ||| CD
±  ||| S:1307 E:1309 ||| CD
0.48 ||| S:1309 E:1313 ||| CD
.  ||| S:1313 E:1315 ||| .
Significant  ||| S:1315 E:1327 ||| JJ
differences  ||| S:1327 E:1339 ||| NNS
were  ||| S:1339 E:1344 ||| VBD
observed  ||| S:1344 E:1353 ||| VBN
between  ||| S:1353 E:1361 ||| IN
male  ||| S:1361 E:1366 ||| JJ
and  ||| S:1366 E:1370 ||| CC
female  ||| S:1370 E:1377 ||| JJ
subjects  ||| S:1377 E:1386 ||| NNS
indicating  ||| S:1386 E:1397 ||| VBG
that  ||| S:1397 E:1402 ||| IN
the  ||| S:1402 E:1406 ||| DT
average  ||| S:1406 E:1414 ||| JJ
percentage  ||| S:1414 E:1425 ||| NN
of  ||| S:1425 E:1428 ||| IN
CD3+  ||| S:1428 E:1433 ||| CD
cells  ||| S:1433 E:1439 ||| NNS
( ||| S:1439 E:1440 ||| -LRB-
p=0.017 ||| S:1440 E:1447 ||| NNP
)  ||| S:1447 E:1449 ||| -RRB-
and  ||| S:1449 E:1453 ||| CC
CD4+  ||| S:1453 E:1458 ||| CD
T  ||| S:1458 E:1460 ||| NN
cells  ||| S:1460 E:1466 ||| NNS
( ||| S:1466 E:1467 ||| -LRB-
p=0.003 ||| S:1467 E:1474 ||| NNP
)  ||| S:1474 E:1476 ||| -RRB-
were  ||| S:1476 E:1481 ||| VBD
higher  ||| S:1481 E:1488 ||| JJR
in  ||| S:1488 E:1491 ||| IN
the  ||| S:1491 E:1495 ||| DT
female  ||| S:1495 E:1502 ||| JJ
population ||| S:1502 E:1512 ||| NN
,  ||| S:1512 E:1514 ||| ,
whereas  ||| S:1514 E:1522 ||| IN
the  ||| S:1522 E:1526 ||| DT
average  ||| S:1526 E:1534 ||| JJ
percentage  ||| S:1534 E:1545 ||| NN
of  ||| S:1545 E:1548 ||| IN
CD19+  ||| S:1548 E:1554 ||| CD
cells  ||| S:1554 E:1560 ||| NNS
( ||| S:1560 E:1561 ||| -LRB-
p=0.02 ||| S:1561 E:1567 ||| NNP
)  ||| S:1567 E:1569 ||| -RRB-
tended  ||| S:1569 E:1576 ||| VBD
to  ||| S:1576 E:1579 ||| TO
be  ||| S:1579 E:1582 ||| VB
higher  ||| S:1582 E:1589 ||| JJR
among  ||| S:1589 E:1595 ||| IN
males ||| S:1595 E:1600 ||| NNS
.  ||| S:1600 E:1602 ||| .
However ||| S:1602 E:1609 ||| RB
,  ||| S:1609 E:1611 ||| ,
investigations  ||| S:1611 E:1626 ||| NNS
on  ||| S:1626 E:1629 ||| IN
the  ||| S:1629 E:1633 ||| DT
CD56+  ||| S:1633 E:1639 ||| NNP
NK  ||| S:1639 E:1642 ||| NNP
cell  ||| S:1642 E:1647 ||| NN
and  ||| S:1647 E:1651 ||| CC
CD8+  ||| S:1651 E:1656 ||| CD
T  ||| S:1656 E:1658 ||| NN
cell  ||| S:1658 E:1663 ||| NN
sub-populations  ||| S:1663 E:1679 ||| NN
did  ||| S:1679 E:1683 ||| VBD
not  ||| S:1683 E:1687 ||| RB
show  ||| S:1687 E:1692 ||| VB
any  ||| S:1692 E:1696 ||| DT
statistical  ||| S:1696 E:1708 ||| JJ
differences  ||| S:1708 E:1720 ||| NNS
between  ||| S:1720 E:1728 ||| IN
the  ||| S:1728 E:1732 ||| DT
two  ||| S:1732 E:1736 ||| CD
genders ||| S:1736 E:1743 ||| NNS
.  ||| S:1743 E:1745 ||| .
In  ||| S:1745 E:1748 ||| IN
comparison  ||| S:1748 E:1759 ||| NN
with  ||| S:1759 E:1764 ||| IN
reports  ||| S:1764 E:1772 ||| NNS
of  ||| S:1772 E:1775 ||| IN
other  ||| S:1775 E:1781 ||| JJ
populations ||| S:1781 E:1792 ||| NNS
,  ||| S:1792 E:1794 ||| ,
we  ||| S:1794 E:1797 ||| PRP
were  ||| S:1797 E:1802 ||| VBD
confronted  ||| S:1802 E:1813 ||| VBN
with  ||| S:1813 E:1818 ||| IN
different  ||| S:1818 E:1828 ||| JJ
results ||| S:1828 E:1835 ||| NNS
.  ||| S:1835 E:1837 ||| .
Establishing  ||| S:1837 E:1850 ||| VBG
reference  ||| S:1850 E:1860 ||| NN
values  ||| S:1860 E:1867 ||| NNS
of  ||| S:1867 E:1870 ||| IN
lymphocyte  ||| S:1870 E:1881 ||| JJ
subsets  ||| S:1881 E:1889 ||| NN
for  ||| S:1889 E:1893 ||| IN
each  ||| S:1893 E:1898 ||| DT
population  ||| S:1898 E:1909 ||| NN
is  ||| S:1909 E:1912 ||| VBZ
helpful  ||| S:1912 E:1920 ||| JJ
in  ||| S:1920 E:1923 ||| IN
achieving  ||| S:1923 E:1933 ||| VBG
standard  ||| S:1933 E:1942 ||| JJ
criteria  ||| S:1942 E:1951 ||| NNS
for  ||| S:1951 E:1955 ||| IN
the  ||| S:1955 E:1959 ||| DT
prognosis  ||| S:1959 E:1969 ||| NN
of  ||| S:1969 E:1972 ||| IN
HIV  ||| S:1972 E:1976 ||| NNP
infection ||| S:1976 E:1985 ||| NN
.  ||| S:1985 E:1987 ||| .
Therefore ||| S:1987 E:1996 ||| RB
,  ||| S:1996 E:1998 ||| ,
normal  ||| S:1998 E:2005 ||| JJ
ranges  ||| S:2005 E:2012 ||| NNS
established  ||| S:2012 E:2024 ||| VBN
by  ||| S:2024 E:2027 ||| IN
this  ||| S:2027 E:2032 ||| DT
survey  ||| S:2032 E:2039 ||| NN
can  ||| S:2039 E:2043 ||| MD
be  ||| S:2043 E:2046 ||| VB
used  ||| S:2046 E:2051 ||| VBN
as  ||| S:2051 E:2054 ||| IN
a  ||| S:2054 E:2056 ||| DT
reference  ||| S:2056 E:2066 ||| NN
for  ||| S:2066 E:2070 ||| IN
decisions  ||| S:2070 E:2080 ||| NNS
made  ||| S:2080 E:2085 ||| VBN
in  ||| S:2085 E:2088 ||| IN
clinical  ||| S:2088 E:2097 ||| JJ
practice ||| S:2097 E:2105 ||| NN
.  ||| S:2105 E:2107 ||| .
